 | |
|---|---|
| Systematic (IUPAC) name | |
| (S)-5-chloro-N-{[2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]oxazolidin-5-yl]methyl} thiophene-2-carboxamide | |
| Clinical data | |
| Trade names | Xarelto |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Licence data | EMA:Link, US FDA:link |
| Pregnancy cat. | C (US) |
| Legal status | POM (UK) ℞-only (US) |
| Routes | oral |
| Pharmacokinetic data | |
| Bioavailability | 80% to 100%; Cmax = 2 – 4 hours (10 mg oral)[1] |
| Metabolism | CYP3A4 , CYP2J2 and CYP-independent mechanisms[1] |
| Half-life | 10 mg oral 7 – 11 hours[1] |
| Excretion | 2/3 metabolized in liver and 1/3 eliminated unchanged[1] |
| Identifiers | |
| CAS number | 366789-02-8 http://www.casbook.com/366789-02-8  |
| ATC code | B01AX06 |
| PubChem | CID 6433119 |
| DrugBank | DB06228 |
| ChemSpider | 8051086  |
| UNII | 9NDF7JZ4M3 |
| ChEMBL | CHEMBL198362 |
| Chemical data | |
| Formula | C19H18ClN3O5S |
| Mol. mass | 435.882 g/mol |
| SMILES | eMolecules & PubChem |
| |
 (what is this?) (verify) | |
Rivaroxaban (BAY 59-7939) is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto.[1] In the United States, it is marketed by Janssen Pharmaceutica.[2] It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
No comments:
Post a Comment